Pin it

Continuous Freedom to Operate: Product Decisions, Platform Rights and Partner Readiness

A biotechnology company has a promising therapeutic candidate and a delivery platform that could support several future programmes. Preclinical work is progressing, manufacturing decisions are becoming more specific, and potential partners are conside ...

Read More
Pin it

Practical Question: Continuous Freedom to Operate. Keeping an Inhaled RNA Platform Clear to Market with Benjamin Winkeljann

Developing an inhaled RNA therapy requires a company to bring several technologies together: the therapeutic RNA, its carrier, the formulation, the manufacturing process and the delivery device. As these elements become a defined product, they also cr ...

Read More
Linkedin
×
Cart